188 related articles for article (PubMed ID: 27581662)
41. Initial experience with genomic profiling of heavily pretreated breast cancers.
Staren ED; Braun D; Tan B; Gupta D; Kim S; Kramer K; Markman M
Ann Surg Oncol; 2014 Oct; 21(10):3216-22. PubMed ID: 25047475
[TBL] [Abstract][Full Text] [Related]
42. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations.
Wheler J; Lee JJ; Kurzrock R
Cancer Res; 2014 Dec; 74(24):7181-4. PubMed ID: 25326492
[TBL] [Abstract][Full Text] [Related]
43. Next generation analysis of breast cancer genomes for precision medicine.
Previati M; Manfrini M; Galasso M; Zerbinati C; Palatini J; Gasparini P; Volinia S
Cancer Lett; 2013 Oct; 339(1):1-7. PubMed ID: 23879964
[TBL] [Abstract][Full Text] [Related]
44. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay.
Fabisiewicz A; Kulik J; Kober P; Brewczyńska E; Pieńkowski T; Siedlecki JA
Acta Biochim Pol; 2004; 51(3):747-55. PubMed ID: 15448736
[TBL] [Abstract][Full Text] [Related]
45. Progress in the clinical detection of heterogeneity in breast cancer.
Song JL; Chen C; Yuan JP; Sun SR
Cancer Med; 2016 Dec; 5(12):3475-3488. PubMed ID: 27774765
[TBL] [Abstract][Full Text] [Related]
46. Fatal microscopic pulmonary tumour embolisms in patients with breast cancer: necessary knowledge for future medical practice.
Vlenterie M; Desar IM; van Herpen CM; Tol J
Neth J Med; 2014 Jan; 72(1):28-31. PubMed ID: 24457436
[TBL] [Abstract][Full Text] [Related]
47. Personalized therapy for breast cancer: a dream or a reality?
Zardavas D; Pugliano L; Piccart M
Future Oncol; 2013 Aug; 9(8):1105-19. PubMed ID: 23902243
[TBL] [Abstract][Full Text] [Related]
48. Is there a role for circulating tumor cells in the management of breast cancer?
Hayes DF; Smerage J
Clin Cancer Res; 2008 Jun; 14(12):3646-50. PubMed ID: 18559576
[TBL] [Abstract][Full Text] [Related]
49. CTCs 'piggyback' off neutrophils.
Killock D
Nat Rev Clin Oncol; 2019 Apr; 16(4):208. PubMed ID: 30787462
[No Abstract] [Full Text] [Related]
50. Heterogeneity of miR-10b expression in circulating tumor cells.
Gasch C; Plummer PN; Jovanovic L; McInnes LM; Wescott D; Saunders CM; Schneeweiss A; Wallwiener M; Nelson C; Spring KJ; Riethdorf S; Thompson EW; Pantel K; Mellick AS
Sci Rep; 2015 Nov; 5():15980. PubMed ID: 26522916
[TBL] [Abstract][Full Text] [Related]
51. Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy.
Khoo BL; Lee SC; Kumar P; Tan TZ; Warkiani ME; Ow SG; Nandi S; Lim CT; Thiery JP
Oncotarget; 2015 Jun; 6(17):15578-93. PubMed ID: 26008969
[TBL] [Abstract][Full Text] [Related]
52. Circulating breast cancer cells are frequently apoptotic.
Méhes G; Witt A; Kubista E; Ambros PF
Am J Pathol; 2001 Jul; 159(1):17-20. PubMed ID: 11438448
[TBL] [Abstract][Full Text] [Related]
53. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.
Magbanua MJ; Pugia M; Lee JS; Jabon M; Wang V; Gubens M; Marfurt K; Pence J; Sidhu H; Uzgiris A; Rugo HS; Park JW
PLoS One; 2015; 10(10):e0141166. PubMed ID: 26496203
[TBL] [Abstract][Full Text] [Related]
54. Tumor heterogeneity-driven individualized therapy.
Baltagiannis EG; Ziogas DE; Cho WC; Mitsis M; Roukos DH
Future Oncol; 2021 Jan; 17(3):235-240. PubMed ID: 33305621
[No Abstract] [Full Text] [Related]
55. Simultaneous detection of clonal expansion of large granular lymphocytes and breast cancer in blood.
Baseggio L; Regad AL; Ffrench M; Felman P
Leuk Res; 2010 Nov; 34(11):e304-5. PubMed ID: 20598744
[No Abstract] [Full Text] [Related]
56. Incorporating functional genomics into the pathology-supported genetic testing framework implemented in South Africa: A future view of precision medicine for breast carcinomas.
Christowitz C; Olivier DW; Schneider JW; Kotze MJ; Engelbrecht AM
Mutat Res Rev Mutat Res; 2024; 793():108492. PubMed ID: 38631437
[TBL] [Abstract][Full Text] [Related]
57. HER2-positive DTCs/CTCs in breast cancer.
Hartkopf AD; Banys M; Fehm T
Recent Results Cancer Res; 2012; 195():203-15. PubMed ID: 22527508
[TBL] [Abstract][Full Text] [Related]
58. Genetic heterogeneity in breast cancer: the road to personalized medicine?
Baird RD; Caldas C
BMC Med; 2013 Jun; 11():151. PubMed ID: 23800221
[TBL] [Abstract][Full Text] [Related]
59. New insights from the widening homogeneity perspective to target intratumor heterogeneity.
Tong M; Deng Z; Zhang X; He B; Yang M; Cheng W; Liu Q
Cancer Commun (Lond); 2018 May; 38(1):17. PubMed ID: 29764517
[TBL] [Abstract][Full Text] [Related]
60. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
